FDA Extends Review Timeline for Ascendis Pharma's Achondroplasia Treatment to February 2026
Key Insights
The FDA has extended the PDUFA goal date for TransCon CNP (navepegritide) by three months to February 28, 2026, following submission of post-marketing requirement information.
Ascendis Pharma submitted information on November 5, 2025, related to post-marketing requirements that the FDA classified as a major amendment to the New Drug Application.
The company has responded to all outstanding FDA requests, including a revised protocol for post-marketing studies discussed at their late-cycle meeting.
Ascendis Pharma announced that the U.S. Food & Drug Administration has extended the review timeline for TransCon CNP (navepegritide), a potential treatment for children with achondroplasia (search), pushing the PDUFA target action date by three months to February 28, 2026.
The extension follows the company's submission of information on November 5, 2025, related to post-marketing requirements as part of the FDA's ongoing review of the New Drug Application. The FDA classified this submission as a major amendment to the NDA, triggering the automatic three-month extension under the Prescription Drug User Fee Act guidelines.
Regulatory Progress and Company Response
"We have responded to all outstanding requests from the FDA, including the request for a revised protocol for the post-marketing study, which we received as the lone item for discussion at our late-cycle meeting," said Jan Mikkelsen, President and Chief Executive Officer at Ascendis Pharma. The company emphasized its commitment to working with the FDA to finalize elements of the post-marketing requirement.
The late-cycle meeting referenced by Mikkelsen indicates the application had progressed through most of the FDA review process, with the post-marketing study protocol being the primary remaining discussion point between the company and regulators.
TransCon Technology Platform
TransCon CNP utilizes Ascendis Pharma's proprietary TransCon technology platform, which the company describes as designed to develop therapies with "best-in-class potential to address unmet medical needs." The Copenhagen-based biopharmaceutical company has positioned this platform as central to its product development strategy across multiple therapeutic areas.
Market Context
Achondroplasia (search) represents a significant unmet medical need in pediatric care, and TransCon CNP could potentially become the first approved treatment specifically targeting this genetic condition in children. The company's goal remains bringing this therapy to U.S. patients "as soon as possible," according to Mikkelsen's statement.
The extended timeline reflects the FDA's thorough review process for pediatric treatments, particularly those addressing rare genetic conditions where post-marketing surveillance requirements play a crucial role in ensuring long-term safety and efficacy monitoring.